• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

GW cancer researchers investigate nanoimmunotherapies for cancer

Bioengineer by Bioengineer
January 28, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Rohan Fernandes, PhD, is leading a team in investigating the efficacy of a nanoimmunotherapy ensemble in treating cancer

WASHINGTON (Jan. 28, 2018) — A team from the George Washington University (GW) Cancer Center has engineered a nanoimmunotherapy that combines the advantages of nanotechnology and immunotherapy to treat cancer. The goal of this nanoimmunotherapy combination is to increase the potency of immune checkpoint inhibitors, a class of immunotherapy that elicits dramatic benefits in only a modest subset of cancer patients, to a significantly larger proportion of patients

Rohan Fernandes, PhD, assistant professor of medicine at the GW School of Medicine and Health Sciences, received more than $1.6 million from the National Institutes of Health for the study. The grant is a R37 award, which is a MERIT — Method to Extend Research in Time — Award for early stage investigators to give them the flexibility and opportunity for creativity and innovation, as well as, additional time to successfully launch their careers.

The researchers will work with Prussian blue nanoparticles (PBNPs) coated with immunological signals, used in combination with checkpoint inhibitors.

Prussian blue is a mixed valence, inorganic nanoparticle that has been historically used as a dark blue pigment. It exhibits unique electrical, optical, and magnetic properties, which make Prussian blue a candidate for several biological, medicinal, and other applications, including photothermal therapy.

“We believe that the ensemble approach to targeting tumor cells and neighboring immune cells using PBNPs hold the key in converting non-responsive, immunologically ‘cold’ tumors into responsive ‘hot’ tumors,” Fernandes said.

After elucidating the effects of PBNPs used for photothermal therapy on the tumor and adjacent immune cells, Fernandes will test the efficacy of the ensemble nanoimmunotherapy on tumor eradication and relapse prevention, and will evaluate the success of nanoimmunotherapy in treating disseminated cancer.

“If we are successful, this study will provide an impetus for clinical translation of our nanoimmunotherapy,” said Fernandes. “We could then achieve our goal of extending lasting benefits to a larger population of cancer patients.”

The team’s nanoimmunotherapy was engineered in collaboration with colleagues at the University of Maryland and Children’s National Health System.

The study, titled “Engineered Ensemble Nanoimmunotherapies for Cancer,” will be funded through November 2022.

###

Media Contact
Ashley Rizzardo
[email protected]
202-994-8679
https://smhs.gwu.edu/news/gw-cancer-researchers-investigate-nanoimmunotherapies-cancer

Tags: cancerCollaborationGrants/FundingMedicine/HealthNanotechnology/MicromachinesResearchers/Scientists/Awards
Share12Tweet8Share2ShareShareShare2

Related Posts

New Study Uncovers Role of Mysterious Variants in Colon Cancer-Linked Gene

New Study Uncovers Role of Mysterious Variants in Colon Cancer-Linked Gene

August 1, 2025
blank

Proteogenomic Study of Healthy vs. Cancerous Prostate Tissues Leveraging SILAC and Mutation Databases

July 31, 2025

CCNY Researchers Identify Possible Chemotherapy-Linked Cognitive Changes in Cancer Survivors

July 31, 2025

Decoding the Mechanisms Behind Chemotherapy Resistance in Bladder Cancer

July 31, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Engineered Cellular Communication Enhances CAR-T Therapy Effectiveness Against Glioblastoma

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary Breakthrough: Achieving Exceptional Performance at Significantly Reduced Temperatures!

Hearing Loss Reduces Employment Opportunities and Earnings Potential for Young Americans

Host-Pathogen Fumarate Control Fuels Staph Pneumonia

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.